Hi @Titan472... We should get an update at the next quarterly, but most will be around 6 months from the commencement of the trial with MO uptake (prescriptions) and possibly revenue. Efficacy and adverse reactions will probably come later. All told we will get a fuller picture in around May next year, leaving a month for data collation.
This is, of course, very approximate and there may be news before these times. I'm only going off my own experience of clinical trials for prescribers. It can often be only 6 months from commencement date (April) especially when the drug itself is not being trialed. With our trial its the capsule and dose strength so MO satisfaction with availability, self-life, dosing issues, efficacy for different doses/strengths etc will be much of the data. Yet MO uptake is going to be key.
cheers Scott.
AC8 Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
